Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires Live12-08

Health care stocks were rising pre-bell Monday, with the iShares Biotechnology ETF (IBB) 0.7% higher and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.

Kymera Therapeutics (KYMR) shares were up more than 38% after the company said a phase 1b clinical trial of KT-62 to treat atopic dermatitis demonstrated "robust clinical activity" that was seen in all disease endpoints.

Arcellx (ACLX) shares were up more than 13% after the company said results of a phase 2 study of anitocabtagene autoleucel, or anito-cel, in patients with relapsed or refractory multiple myeloma showed a 96% overall response rate.

BioNTech (BNTX) stock was up more than 3% after the company and OncoC4 said their experimental therapy, gotistobart, showed a "meaningful" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589057356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589057356","market":"hk","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Rise Pre-Bell Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were rising pre-bell Monday, with the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.7% higher and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.</p><p>Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) shares were up more than 38% after the company said a phase 1b clinical trial of KT-62 to treat atopic dermatitis demonstrated \"robust clinical activity\" that was seen in all disease endpoints.</p><p>Arcellx (ACLX) shares were up more than 13% after the company said results of a phase 2 study of anitocabtagene autoleucel, or anito-cel, in patients with relapsed or refractory multiple myeloma showed a 96% overall response rate.</p><p>BioNTech (BNTX) stock was up more than 3% after the company and OncoC4 said their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Rise Pre-Bell Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Rise Pre-Bell Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Health care stocks were rising pre-bell Monday, with the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.7% higher and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.</p><p>Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) shares were up more than 38% after the company said a phase 1b clinical trial of KT-62 to treat atopic dermatitis demonstrated \"robust clinical activity\" that was seen in all disease endpoints.</p><p>Arcellx (ACLX) shares were up more than 13% after the company said results of a phase 2 study of anitocabtagene autoleucel, or anito-cel, in patients with relapsed or refractory multiple myeloma showed a 96% overall response rate.</p><p>BioNTech (BNTX) stock was up more than 3% after the company and OncoC4 said their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589057356","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589057356","pubTimestamp":1765203384,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were rising pre-bell Monday, with the iShares Biotechnology ETF  0.7% higher and the Health Care Select Sector SPDR Fund  up 0.1%.Kymera Therapeutics  shares were up more than 38% after the company said a phase 1b clinical trial of KT-62 to treat atopic dermatitis demonstrated \"robust clinical activity\" that was seen in all disease endpoints.Arcellx  shares were up more than 13% after the company said results of a phase 2 study of anitocabtagene autoleucel, or anito-cel, in patients with relapsed or refractory multiple myeloma showed a 96% overall response rate.BioNTech  stock was up more than 3% after the company and OncoC4 said their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","IBB":"生物科技指数ETF-iShares Nasdaq","BK4535":"淡马锡持仓","BK4139":"生物科技","KYMR":"Kymera Therapeutics, Inc.","ACLX":"ARCELLX, INC.","BK4581":"高盛持仓","LABU":"三倍做多标普生物-Direxion","XBI":"SPDR S&P Biotech ETF","XLV":"健康照护类股ETF-SPDR","BNTX":"BioNTech SE","BK4568":"美国抗疫概念"},"translate_title":"行业更新：医疗保健股周一盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"ACLX":1,"KYMR":1,"XBI":0.6,"IBB":1,"LABU":0.6,"XLV":1},"content_text":"Health care stocks were rising pre-bell Monday, with the iShares Biotechnology ETF (IBB) 0.7% higher and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.Kymera Therapeutics (KYMR) shares were up more than 38% after the company said a phase 1b clinical trial of KT-62 to treat atopic dermatitis demonstrated \"robust clinical activity\" that was seen in all disease endpoints.Arcellx (ACLX) shares were up more than 13% after the company said results of a phase 2 study of anitocabtagene autoleucel, or anito-cel, in patients with relapsed or refractory multiple myeloma showed a 96% overall response rate.BioNTech (BNTX) stock was up more than 3% after the company and OncoC4 said their experimental therapy, gotistobart, showed a \"meaningful\" overall survival benefit in certain metastatic squamous non-small cell lung cancer patients during the non-pivotal stage of the global phase 3 trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589057356","isCrawlerRequest":true}